How to Evaluate Hair-Loss Treatments: The Evidence Boundaries for Propecia, Proscar, Rogaine, and Hair-Growth Products

An Evidence Map for Hair-Loss Treatment: Active Ingredients, Medication Risks, and the Limits of Marketing Claims

Bottom line

Male androgenetic alopecia has standard treatments supported by clinical research. However, claims about tablet splitting, absolute safety, extrapolation from animal studies, and commercial products cannot borrow the efficacy evidence for an active ingredient and present it as proof of those separate claims.（PMID: 9777765）

First determine which type of hair loss is being discussed

“Hair loss” is not a single disease. Professor Ching-Shuang Lin’s original article addresses medication for male androgenetic alopecia, topical hair-growth treatments, media amplification of animal research, and efficacy claims for specific products. Before accepting any assertion that something “works” or “does not work,” ask whether the study involved humans, the scalp, and androgenetic alopecia, and identify the exact ingredient and method of use that were studied. If even one of these elements differs, the conclusion cannot simply be transferred unchanged.

The literature supports finasteride and minoxidil as important standard treatments for androgenetic alopecia. However, broadly stating that “only these two are approved” under all circumstances overlooks differences in disease subtype, sex, formulation, and the regulatory definitions applied to drugs or devices. A more precise formulation must therefore preserve the relevant scope of use.（PMID: 41779757）

Evidence for the efficacy and dosage of finasteride

For male androgenetic alopecia, the efficacy of finasteride at 1 mg daily is supported by randomized trials and literature reviews. This is also consistent with the historical position in Professor Lin’s original article, which regarded the hair-growth effect of Propecia as established.（PMID: 9777765）（PMID: 12894990）

Yet “the same active ingredient” and “any product becomes an equivalent formulation after splitting” are two different propositions. Cutting a 5 mg Proscar tablet into four pieces yields a nominal dose of approximately 1.25 mg, which is arithmetically close to 1 mg. That calculation does not answer questions about disruption of the film coating, uniformity of drug content among the pieces, storage after splitting, or whether different products retain the same quality. This ECU found no usable product-specific evidence on stability, content uniformity, or clinical equivalence. The efficacy trials for Propecia 1 mg therefore cannot serve as proof for every split-tablet product.（PMID: 9777765）

This boundary does not reject the reasoning in Professor Lin’s original article. It distinguishes the practical judgment that “with similar doses, efficacy and adverse effects should not differ greatly” from the claim that “the quality and clinical equivalence of the split product have been directly verified.” The former is an inference based on similar dosage; the latter requires studies of the split product itself. Anyone considering this dosing practice should ask a physician and pharmacist to assess the actual product, storage method, and individual prescription together.

How to describe sexual and mood symptoms accurately

Reports of sexual or mood symptoms persisting after finasteride discontinuation do exist, and neither regulatory labeling nor case reports should be ignored. On the other hand, a substantial portion of the available evidence comes from self-reports or case series, and neither the causal mechanism nor the incidence has been settled. Professor Lin preserved this uncertainty by noting disagreement and a lack of consensus within medicine, a position compatible with the two-sided limitations presented in current reviews.（PMID: 32435662）（PMID: 35983808）

It is therefore inaccurate to say that “all symptoms have been proven to be caused by the drug,” while saying that “symptoms can never persist after discontinuation” likewise goes beyond the evidence. A more evidence-based statement is that a safety signal indicating this possibility exists, but clinical assessment is still required to determine whether a particular symptom was caused by the medication and how large the risk may be. Before starting or stopping a prescription drug—especially when sexual or mood changes have already occurred—patients should consult a physician instead of drawing conclusions solely from online anecdotes.

Topical minoxidil: standard treatment does not mean zero risk

Topical minoxidil is part of standard therapy for androgenetic alopecia, but “topical” does not automatically mean that adverse effects must remain local or must resolve after discontinuation. Nor does it establish the complete absence of cardiovascular or irreversible adverse effects. The review retrieved for this ECU does not provide sufficient evidence about the long-term adverse effects of conventional topical minoxidil, and the available data cannot support such an absolute guarantee of safety.（PMID: 42398233）

This point should be understood in the context of scientific progress. Professor Lin’s original discussion of a topical preparation was intended to reassure readers that they need not be excessively concerned about irreversible adverse effects. With today’s updated literature, the statement is better narrowed to “use it correctly and monitor the response” rather than “serious problems are impossible.” A standard treatment has an established basis for assessing benefit and risk; it does not mean that every user is free of contraindications, interactions, or abnormal reactions that require medical attention.

Hair growth in mice is not hair regrowth on the human scalp

Research on topical monounsaturated fatty acids is mechanistic hair-regeneration research. The available abstract provides no efficacy data for human scalp androgenetic alopecia or for hair regrowth in humans within 20 days. Media reports that turn this directly into “hope for people with baldness” or a treatment ready for use on the human scalp cross the boundary of what the research actually supports. Professor Lin’s refusal to package such findings directly as a clinical product is consistent with the level of evidence.（PMID: 41130201）

Hair on the backs of mice and androgenetic alopecia of the human scalp are not interchangeable models. Evidence capable of answering whether a treatment works in humans must come from appropriately matched human trials of androgenetic alopecia. Mechanistic research can point toward promising directions, but it cannot independently prove that patients will grow hair after using a product. Separating these types of research is essential to avoid mistaking an early finding for an available therapy.（PMID: 41051009）（PMID: 41130201）

Verifying Thymuskin and the claim of “multiple supporting studies”

Thymuskin has been promoted as a product that stops hair loss and initiates new hair growth, with “multiple clinical studies” invoked to make the claim persuasive. However, ECU searches combining the product name with hair loss and clinical-trial terms found no verifiable systematic review, randomized trial, or clinical study sufficient to substantiate that claim. This agrees with Professor Lin’s observation that the manufacturer’s pooled evaluation lacks a traceable source and that searches by product name do not retrieve adequate medical literature. Failure to find supporting evidence does not prove that the product is necessarily and completely ineffective; it means that strong efficacy claims cannot currently be treated as established.

Regarding prevention of hair loss caused by cytotoxic chemotherapy, a bibliographic record for an older German-language paper from 1986 does exist, but the core record currently contains neither an abstract nor results. A title alone can neither establish that the product works nor fully verify how the original article characterized the study’s conclusion. Until the full text and verifiable results are available, the evidence-based judgment remains that evidence is insufficient.（PMID: 3543781）

Applying this evidence to personal decisions

Begin by establishing the diagnosis, then check whether the therapy, formulation, and method of use match those studied. For standard treatments supported by human trials, discuss expected benefits, possible adverse effects, and follow-up with a physician. Tablet splitting adds questions about content uniformity, film coating, storage, and the actual product used. For new ingredients reported in the news, determine whether research has advanced from mechanistic or animal work to trials on the human scalp. For commercial products, ask for traceable study names, study designs, and complete results.

Overall, the most important principle to preserve from Professor Lin’s article is that media slogans and manufacturers’ promotions are not clinical evidence. As the literature has evolved, we can add clearer scopes and uncertainties: evidence for finasteride efficacy in humans does not prove every tablet-splitting plan equivalent; topical minoxidil is a standard treatment but does not warrant an absolute safety guarantee; and early hair research has scientific value but is not yet a therapy for human hair loss.（PMID: 9777765）（PMID: 41779757）（PMID: 41130201）